Drugs / Erythropoietin Beta
Erythropoietin Beta
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00551291 | Aug 2007 → Jun 2009 | myelodysplastic syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00140010 | Apr 2005 → Mar 2007 | acquired aneurysmal subarachnoid hemorrhage | University of Cambridge | Completed | Mixed |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00284271 Background | Jan 2004 → Dec 2005 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2/3 | NCT00654992 Comparator | Sep 2006 → Feb 2008 | acute kidney injury | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01732146 Comparator | Mar 2013 → Feb 2017 | brain hypoxia - ischemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | erythropoietin beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00140010 ↗ |
| Known as | Epoetin beta | “This study is a randomized, double-blind, placebo-controlled clinical trial investigating the potentially beneficial effects of systemic recombinant human erythropoietin...” NCT00140010 ↗ |
| Known as | NeoRecormon | “This study is a randomized, double-blind, placebo-controlled clinical trial investigating the potentially beneficial effects of systemic recombinant human erythropoietin...” NCT00140010 ↗ |
| Action | Activate | “By activation of endothelial EPO receptors” NCT00140010 ↗ |
| Modality | Protein / enzyme biologic | “Epoetin beta is a 165-aa glycoprotein manufactured by using recombinant DNA technology” NCT00140010 ↗ |
| Route | Intravenous | “30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage” NCT00140010 ↗ |